Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
In silico studies-assisted design, synthesis, and discovery of biologically active isatin derivatives
Abstract
Purpose: To design isatin-based compounds, carry out in silico studies, and identify the biologically active isatin derivatives.
Methods: Fourteen isatin-based compounds (A to N) were designed using ChemDraw. In addition, in silico studies (molecular docking, prediction of drug likeliness, gastrointestinal absorption, log P, and toxicity) of the designed compounds were compared to ciprofloxacin. Based on the results of the in silico studies, three compounds (G, H, and L) were selected for synthesis, and the chemical structures of G, H, and L were elucidated via spectral analysis. The antimicrobial activity and DNA gyrase inhibitory activity of G, H, and L were evaluated and compared to those of ciprofloxacin.
Results: The docking scores of compounds G, H, and L (-5.90, -5.72, and -5.98 kcal/mol, respectively) were comparatively better than that of ciprofloxacin (-5.41 kcal/mol). In silico studies data also revealed the non-hepatotoxic nature, drug-likeliness properties, and good gastrointestinal absorption for G, H, L, and ciprofloxacin. The in vitro antimicrobial activity (p < 0.05) and DNA gyrase inhibitory activity of G (102.33 %, p < 0.05), H (104.43 %, p < 0.05), and L (106.77 %, p < 0.05) were better than those of ciprofloxacin (100.0 %, p < 0.05).
Conclusion: Compounds G, H, and L are promising DNA gyrase inhibitors. These compounds should be explored further to determine their broad-spectrum antimicrobial potency, safety, and efficacy.
